Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. Founded in 2005 through the merger of two century-old Japanese pharmaceutical companies, Daiichi Sankyo is the second-largest pharmaceutical company in Japan achieving JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent and has subsidiaries in the U.S., Europe and other regions. Industries it has a preference for include: Biotechnology, Healthcare, Medical Devices & Equipment, Pharmaceuticals It's preferred route(s) to market include: Primary Funds. First time funds may be considered.